Amongst the research being presented is 'Stress Reduction in Children', a Mars-funded study in which 75 male children were monitored to see how their levels of the stress-hormone cortisol varied when they were exposed to mild social stresses. The study found that children with a dog present showed significantly lower levels of the stress-hormone than those with a friendly adult present. In addition, the more the children stroked and interacted with the dog, the further their levels of cortisol decreased.
Sandra McCune, Research Manager for the Human-Companion Animal Bond Research Programme at Mars Petcare's Waltham Centre for Pet Nutrition (there's a job title-and-a-half) said: "Pet owners will tell you just how much their pet means to them but it is research such as this that proves just how fundamental and important the bond is between people and pets. These studies provide us with valuable insight into this special bond and the health benefits of owning a pet."
The findings of a Canine Vector Borne Disease (CVBD) prevention field study, published in Veterinary Parasitology today, have demonstrated the efficacy of Advantix in repelling ticks and sandflies, thus reducing the risk of potentially deadly diseases.
The study, conducted over two years by a team headed by Professor Domenico Otranto of the Faculty of Veterinary Medicine (Universitá degli Studi di Bari) Italy, with diagnostic support from a team led by Dr. Edward Breitschwerdt at the North Carolina State University, USA, found that dogs treated regularly with Advantix spot-on had a greater than 90% reduction in CVBD cases, including a 100% reduction in new cases of potentially deadly leishmaniosis and a 94.6% decrease in ehrlichiosis.
The study also found that Advantix provided 97.9% protection against tick infestation, compared to untreated dogs, where 100% were infested at the peak of the season. The level of protection offered by Advantix was apparently all the more notable because of particularly large numbers of ticks and sand flies and high prevalence of associated diseases like leishmaniosis or babesiosis in the area of the study.
Prof. Otranto said: "Our study shows the importance of protecting dogs with an effective treatment that repels as well as kills parasites like ticks and sand flies. Despite the high challenge faced by the dogs in our study, nearly all our treated dogs remained free from ticks throughout most of the study, and more than 90% remained free from CVBDs for the whole study time.
"Because we included naïve sentinel beagles in the study, we were also able to model what would happen to dogs travelling to areas where CVBDs are present. We found that by the end of the study, only the Advantix-treated beagles remained protected from infection, while 80% of the untreated beagles were infected with a CVBD. This demonstrates the very real need to protect dogs that are travelling to endemic areas."
According to Bayer, the study showed some interesting results with dogs that were positive with CVBDs when they entered the study. Of these, half of those treated with Advantix were negative for CVBDs at the end of treatment, compared with only 13% of untreated dogs. This suggests the potential for natural clearance of CVBDs if a repellent treatment is used to prevent new transmissions.
Bayer says the study was extremely comprehensive, studying both indigenous and introduced naïve puppies, monitoring for several CVBDs and working with Dr. Breitschwerdt's team in the USA to use highly sensitive molecular testing techniques to ensure optimal diagnostic accuracy. Dr. Breitschwerdt said: "This is the most comprehensive study, to my knowledge, ever conducted testing the efficacy of a repellent ectoparasiticide to prevent the transmission of a spectrum of CVBDs in young dogs."
Leading parasitologist Dr. Luis Cardoso of the University of Trás-os-Montes e Alto Douro, Portugal said: "Thanks to this study we can see just how effective a treatment that repels as well as kills can be."
John Swinney MSP, Cabinet Secretary for Finance and Sustainable Growth, oficially opened the award-winning £10.5 million Small Animal Hospital for the Faculty of Veterinary Medicine, University of Glasgow today.
Designed by Archial Architects, the Small Animal Hospital provides state of the art services for animal owners and referring practitioners throughout Scotland and Northern England, including advanced diagnostic, therapeutic and surgical techniques.
Archial's design for the Small Animal Hospital has already won a string of awards, including the prestigious RIAS Andrew Doolan Best Building in Scotland Award, a RIBA Regional Award and the Supreme Award from the Glasgow Institute of Architects.
Archial Architects has confirmed that it is to donate £2,500 from the Andrew Doolan Prize fund to the Small Animal Hospital.
For veterinary surgeons and VNs who missed out on the BVDA 'Improving Periodontal Health' lecture tour last year, a further six have been organised for this autumn.
Speakers include Norman Johnston BVM&S, MRCVS, Ex President of the European Veterinary Dental College, John Robinson BDS (Lond) Dentist to the Veterinary Profession and Lisa Milella BVSc, MRCVS President of the British Veterinary Dental Association (BVDA). This year's events see the content extended to include resorptive lesions, fractured teeth and dental radiography with greater emphasis on feline oral care.
According to Lisa, the 2010 lecture series helped alert vets and VNs to the importance of oral health, benefitting both pet and practice. "It takes five years at vet school to qualify yet only three or four days are devoted to dentistry, so it's no surprise that many vets and VNs enter the profession with only a basic understanding of oral health.
"We know that four out of five dogs over the age of three show signs of periodontal disease but unfortunately many go untreated. This is mainly because the problems that this can lead to are not fully understood."
She added: "These seminars will not only help delegates to recognise early signs of oral disease but also offer practical guidance on how practices can educate pet owners in the importance of oral care."
Lisa believes that both practices and owners benefit from good oral hygiene programmes. "As a profession we need to do more to help educate pet owners in the value of good oral care. Practices should be talking to their clients from day one about preventative programmes, rather than wait until the damage is done."
The six UK events are:
The evening seminars, which are open to both vets and nurses, contribute two hours CPD and cost £35 per person and £25 for each subsequent delegate. A special group rate of £100.00 is available for any practice that wishes to send a group of four. For anyone wanting to reserve a place, please call the BVDA lecture tour reservation line centre on 01664 415 503.
Dechra Veterinary Products has produced a pair of presentations, aimed at pet owners, for vets to use in receptions and at client events. The presentations cover canine hyperadrenocorticism, aka Cushing's syndrome, and feline hyperthyroidism.
Matthew Olsen, Product Manager, said: "We are committed to delivering a wide range of support materials and tools to enable vets to provide help and information to their customers. We have developed an owners' booklet on both Cushing's and hyperthyroidism and have now backed this up with PowerPoint presentations for vets to use with their clients. Some veterinary practices are using technology to revolutionise waiting room displays and we have responded to their needs by producing a presentation they can use on their waiting room information screens."
The Dechra Hyperadrenocorticism presentation covers what Cushing's is, what causes it and what owners need to look for. The presentation also explains the treatment options available. The Hyperthyroidism presentation details what the condition is and gives information on the thyroid gland. It highlights what cat owners need to look out for, including weight loss in spite of a ravenous appetite, increased fluid intake and increased restlessness. The presentation also advises people of what to do should they suspect their cat has hyperthyroidism and what the treatment options are.
Garden Lodge Veterinary Clinic in Holywood, County Down, has used the Hyperthyroidism presentation at both its practices. Partner Tom Fitzsimons said: "We have used the presentation on our reception information screens. The presentation has raised owners' awareness and shown them it is a manageable condition. It's led to an increase in the number of cats we are now testing for Hyperthyrodism. We also plan to run the Cushing's presentation in the future."
Veterinary Practices interested in getting hold of a free copy of the Hyperthyrodism and Hyperadrenocorticism presentations should contact Matthew Olsen at Dechra on 01743 441 632 or email matthew.olsen@dechra.com
Animalcare has launched a new broad spectrum fluoroquinolone antimicrobial (Enrofloxacin) which the company says is highly effective in the treatment of a wide range of conditions and easy to inject, with excellent tissue penetration.
Enrocare solution for injection is presented in three strengths: A 25mg/ml (2.5%) injection for dogs, cats and exotic animals including reptiles, small mammals and avian species. The 50mg/ml (5%) injection is licensed for use in cattle, pigs, dogs and cats, whilst the 100mg/ml (10%) injection is licensed for cattle and pigs. In the case of dogs and cats a single daily dose is needed.
Animalcare says it has priced Enrocare competitively. In addition, the range has been launched with three offers: "Buy one get one free on the 50 and 100mg/ml" and "Buy two get one free offer" on the 25mg/ml pack size. These offers will last for four months until the end of September.
In cattle, Enrocare 50mg/ml, given by the subcutaneous route, is licensed for respiratory disease of bacterial or mycoplasmal origin and the 100mg/ml strength is licenced for both respiratory disease and E.coli mastitis (the latter given by slow intravenous injection). According to Animalcare, its low dose volume makes it particularly suitable for the treatment of respiratory disease in calves. In pigs >25kg Enrocare is licensed for the treatment of the respiratory and alimentary tract diseases of bacterial or mycoplasmal origin and multi-factorial diseases such as atrophic rhinitis and enzootic pneumonia.
Tony Liepman, Animalcare Market Manager said: "The recent successful launch of Cephacare flavour raised Animalcare's profile as a supplier of more up-to-date antibiotics and this is our latest addition which offers excellent efficacy at an attractive price."
The EU Commission has approved the marketing authorisation variation of Boehringer Ingelheim's PCV2 vaccine Ingelvac CircoFLEX. This approval allows the combined use of the pig vaccines Ingelvac CircoFLEX and Ingelvac MycoFLEX in the European Union.
Boehringer says it will market this unique vaccine concept under the name FLEXcombo. The company highlights that protection against two of the most prominent and costly pig diseases, Porcine Circovirus Disease (PCVD) and Enzootic Pneumonia, can now be achieved with a single injection instead of up to four injections. More than 70% of European pigs are currently vaccinated against both these diseases.
According to the company, the combined use of Ingelvac CircoFLEX and Ingelvac MycoFLEX is already registered and widely used in North America and Asia. It is globally the first and only product combination of its kind.
Dr. Joachim Hasenmaier, global head of Animal Health within BI said: "We are very proud that we can now also supply EU veterinarians and farmers with this latest innovation that will help tremendously in reducing the number of injections to pigs, supporting the wellbeing of the animals and the farm economics by saving a substantial amount of labour."
Dechra Pharmaceuticals has signed an agreement with Piedmont Pharmaceuticals LLC which gives Dechra exclusive worldwide rights to the sale and distribution of veterinary products which use Piedmont's proprietary soft chew platform to deliver the active ingredient.
The agreement will allow Dechra to conduct studies necessary to achieve regulatory filings and government approvals within the US, Europe and other key countries.
According to Dechra, Piedmont's soft chew formulation is a unique delivery technology which overcomes the traditional problems in formulating a broad range of active drug compounds in a highly palatable chewy treat for both cats and dogs.
Ian Page, CEO of Dechra Pharmaceuticals PLC, said: "We are very excited about licensing this unique delivery technology, which will be the first soft chew product with this new patent pending technology in the veterinary market. The agreement will provide Dechra with the opportunity to expand our presence in the companion animal market with a truly differentiated product."Roland Johnson, Chairman and CEO of Piedmont Pharmaceuticals, said: "This is our initial development partnership for our soft chew technology and we welcome the opportunity to license our technology to Dechra. Our goal is to provide pet owners the added benefit of a tasty treat at medicine time, creating a fun and rewarding interaction, while improving compliance with the vet prescribed treatment regimen."
Rob Rayward, an RCVS Orthopaedic Specialist at Davies Veterinary Specialists, Hertfordshire, is preparing to grease up and swim the murky waters of the English Channel this month, to raise funds for the Christian charity Derek Prince Ministries UK.
Rob is undertaking the 35km swim as a part of a Channel Swim Relay Team and has been in training for his chilly trip across one of the world's busiest shipping lanes for the past year. He is hoping to raise £1500 for the charity, which provides Christian teaching materials in over 1000 languages to Church leaders and Christian communities around the world. They also provide food and education to poor widows and orphans in Ethiopia.
Rob said: "Despite being a small animal vet I'm definitely not planning on doing the doggy paddle. All members of the team have different strengths and weaknesses but for me the cold water is proving to be a real challenge. It is likely to be about 16C on the day but as well as the cold we may have to swim part of it in the dark. Many people are aware that the Channel has debris floating in it but few are aware that we may also face jelly fish, basking sharks and if really lucky, sewage! We anticipate it taking us approximately 14 hours to complete the crossing but weather and tidal conditions can have a major impact on our time."
Rob will be completing his challenge when the conditions are favourable at some point between 19th and 28th July.
To sponsor him visit his JustGiving page at www.justgiving.com/rob-rayward.
All donations are gratefully received.
Agrimin has announced the launch of a new range of boluses for sheep and cattle that use 'eroding technology' to deliver a sustained supply of three trace elements for up to 180 days:
According to Agrimin, each bolus is designed to provide the full daily requirement of cobalt and selenium and the largest available daily supply of iodine to both cattle and sheep. The boluses do not contain any copper, an element known to cause issues in certain parts of the country, in closely managed dairy cows or in continental sheep breeds.
Each bolus is made up of two parts, held together by a soluble wrapper. After administration, the wrapper dissolves and the two halves remain in the reticulum where they erode and dissolve. This process delivers a continuous and regular supply of nutrients to the animal.
Agrimin's Dr Jamie Bennison said that the new range has been extensively trialled in New Zealand and at Glasgow Veterinary School: "Trials have confirmed a sustained release profile which ensures that iodine, selenium and cobalt levels are maintained throughout the active life of the bolus. In farm trials this has translated into higher levels of the elements in blood samples and improved animal productivity."
Treatment is one bolus per animal (48g for sheep; 160g for cattle) administered with an Agrimin bolus gun. One bolus is sufficient to meet the animal's full daily requirement for 180 days.
For more information about the 24•7 Iodine•Selenium•Cobalt range of cattle and sheep boluses, please visit http://www.agrimin.com/ or call 01652 688046.
The International Society of Feline Medicine (ISFM) has published 'Consensus Guidelines on the Long-term use of NSAIDs in cats' in the July 2010 edition of the Journal of Feline Medicine and Surgery.
The society says it has developed the guidelines in order to try and address the major welfare issue of cats suffering unremitting and untreated chronic pain. Until recently, NSAIDs had only been licensed for short-term use in cats, but with changing licensing indications and recommendations, they are now also increasingly used for long-term treatment of cats, for example in the management of osteoarthritis.
However, in most cases where long-term use of pain relief in cats is required, there are concomitant problems with other diseases or other drugs that are being given. According to the ISFM, one of the most common concerns is whether NSAIDs can be used to treat arthritis in older cats with kidney disease. The society says that because of concerns like these, and the potential for adverse effects, cats often receive no treatment at all, and their quality of life can be severely compromised.
For this reason, the ISFM set up an international expert panel to develop practical and rational guidelines on the long-term use of NSAIDs in cats. The aim was to provide guidelines that would empower clinicians, enabling them to make sensible and rational choices, and ensure much-needed therapy is not needlessly withheld from patients.
The panel was made up of Andrew Sparkes, Duncan Lascelles, Richard Malik, Sheilah Robertson, Margie Scherk, Polly Taylor, Llibertat Real Sampietro and Reidun Heiene.
Along with the veterinary information in the guidelines, the panel also developed a brief client-facing leaflet that can be given to owners when NSAIDs are prescribed for their cats - this leaflet provides simple, clear advice on why NSAIDs are used, why they are important, but also what simple precautions avoid adverse effects, with further advice on when to seek veterinary advice to reinforce the safety message.
Both of these publications are available to download from the website www.isfm.net/toolbox
Genitrix has announced the launch of Prilben (benazapril hydrochloride). The product joins its 'Standards' range, created to offer veterinary practices cost-effective versions of frequently used products.
Prilben is indicated for the treatment of congestive heart failure in dogs and for chronic renal insufficiency in cats. It is provided in packs of 14 x 5mg tablets at a veterinary list price of £4.50, which equates to 32p per tablet.
Rob Watkins, Marketing Director at Genitrix, said: "Benazapril hydrochloride is a tried and trusted medicine used in countless practices and homes across the country every day. Prilben offers a win for both practices and pet owners because its pricing structure enables practices to maintain profitability on the product whilst still providing their clients with an economical alternative."
The first product in Genitrix' Standards range, Dormilan, was launched in late 2009 and offers fast-acting sedation and analgesia for dogs and cats.
CEVA Animal Health has published an information booklet on Q Fever to help broaden awareness and understanding of the disease.
Q Fever is an emerging, worldwide disease that affects goats, cattle and sheep as well as humans. It is caused by the bacterium Coxiella burnetii and can induce late abortions, metritis, fertility problems, mastitis and low vitality in neonates born from carrier animals.
The new booklet explains how the disease is transmitted, the symptoms, diagnosis and how it can be managed and prevented. CEVA already have expertise in the treatment of diseases caused by Coxiella burnetii and have developed a vaccine that has been used under temporary license to control outbreaks in France and the Netherlands.
To obtain a copy of the booklet please contact CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG. The proceedings from CEVA's recent symposium on Q fever, held in Marseilles in December 2009 are also available on request.
CEVA Animal Health has published a trial which, according to the company, shows that horses suffering lameness caused by bone spavin can show marked improvement following treatment with a Tiludronate infusion, in combination with controlled exercise.
Bone spavin is a chronic aseptic osteoarthritis of the distal tarsal joints which, says CEVA, is considered to be one of the most common forms of hindlimb lameness in the horse.
The double-blind, multicentric, placebo-controlled trials were carried out on a total of 108 pleasure horses, show jumpers and eventers of a variety of sizes and breeds, all of which had been clinically diagnosed with bone spavin. The horses were rigorously selected, having to show clinical signs of spontaneous lameness of at least six weeks but less than a year's duration and had to be in daily exercise. Horses suffering proximal suspensory desmitis were excluded.
Horses were defined as suffering from bone spavin if they displayed a chronic hindlimb lameness which improved with distal tarsal joint analgesia and showed radiographic evidence of bony changes associated with bone spavin in the distal tarsal joints. The horses were treated at day zero with a single Tiludronate infusion or a placebo and reassessed 60 days later after a period of controlled exercise.
Eighty seven horses completed the trials, comprising 42 Tiludronate treated horses and 45 placebo cases. By day 60 approximately 60% of the Tiludronate treated horses had improved in lameness by two grades or more, scored on a ten point system.
Horses with bone spavin experience abnormal bone remodeling changes, occasionally with excessive bone resorption in the tarsal bones. Tiludronate works by regulating this bone remodeling through a decrease in the resorptive process, slowing down the degradation of the bone structure when the condition is progressing and alleviating the pain associated with abnormal bone lysis.
CEVA has recently produced a leaflet specifically to help horse owners to understand the diagnosis and treatment of bone spavin. For copies of this leaflet and CEVA's comprehensive veterinary brochure on the product please contact CEVA Animal Health on 01494 781510 or visit the website at http://www.tildren.com/
Tiludronate infusion in the treatment of bone spavin: A double blind placebo-controlled trial
Reference M. R. GOUGH*, D. THIBAUD† and R. K. W. SMITH‡ (*CEVA Animal Health, Bucks, UK; †CEVA Animal Health USA, Kansas, USA; and ‡Department of Veterinary Clinical Sciences, The Royal Veterinary College, University of London, UK). Equine vet. J. (2010) 42 (5) 381-387 doi: 10.1111/j.2042-3306.2010.00120.x
Vets Now has this month launched a new fast track programme called 'Cutting Edge', which the company says is aimed at young, dynamic vets.
The 'Cutting Edge' initiative is apparently the first training programme of its kind in the UK and will see 40 graduates who graduated between 2006 and 2009 recruited into a 10 week fast track training programme, before they take up permanent positions in Vets Now clinics. Each recruit will get a salary package which will put them on £40k within 24 months.
Interviews and selection will be held mid-late August at a number of selection centres across the UK, with the first intake of 20 recruits commencing their fast track training programme on 4 October and taking up their positions in a Vets Now clinic in December.
A second intake of recruits to the programme will be selected during November, with these recruits taking up their positions on the fast track training late in January.
The programme is being spearheaded by Vets Now Clinical Director and experienced clinician and teacher in Emergency and Critical Care, Amanda Boag, MA VETMB DipACVIM DACVECC FHEA MRCVS who said: "This is a unique and hugely exciting opportunity for recently qualified vets to enter the field of Emergency and Critical Care. We're looking for dynamic and energetic young vets with a real passion for continuing their clinical development who feel they have what it takes to succeed in this exciting, and growing sector of veterinary medicine."
She added: "The recruits who we select will embark upon an intensive period of training over the 10 week period which will give them the necessary skills and knowledge to launch their career in ECC. They will also receive ongoing support during their first two years as a veterinary surgeon in a Vets Now clinic with a very generous CPD allowance. The initial 10 week period will be a combination of lectures and interactive seminars, practical training in our clinical skills laboratory and mentored work in our clinics. Developing clinical expertise and problem solving skills will clearly be the most significant component of the training but there will also be support and training in other vital skills including communication."
Until now, Vets Now would only employ veterinary surgeons with at least two years post-qualified small animal experience or who have completed their PDP. This new programme has been launched to attract and support young talent in making the move to this growing sector of veterinary medicine.
Recent graduates who are interested in developing a career in ECC are invited to apply in the first instance by contacting the Vets Now recruitment team on 01383 841181 or by emailing cuttingedge@vets-now.com.
The new initiative also has a Facebook page - www.facebook.com/vetsnowcutting edge and you can follow news and updates on the 'Cutting Edge' Twitter page at www.twitter.com/vncuttingedge.
The Disciplinary Committee of the Royal College of Veterinary Surgeons has suspended a veterinary surgeon from the Register for nine months for convictions regarding docking puppies' tails and driving offences, and for failing to obtain a client's consent to treatment or explore other treatment options.
At the conclusion of the four-day hearing, Dr Adetunji Ayinla Jolaosho, formerly principal veterinary surgeon at City Vet Clinic in Syston, near Leicester, was found unfit to practise following two convictions for tail docking plus 17 driving and related offences, which also brought the profession into disrepute.
They further found that he failed to obtain consent to remove tissue from Jemma, a Staffordshire Bull Terrier owned by Mrs Hill, and to discuss a reasonable range of treatment options with her, and that this also amounted to serious professional misconduct.
In December 2008, Mrs Hill brought Jemma to Dr Jolaosho to have a lump on her flank drained. Mrs Hill said she made it clear that she had limited finances and nothing other than this treatment should be done without her consent. Dr Jolaosho undertook a biopsy and removed tissue. He told the Committee that he asked his practice manager to contact Mrs Hill and obtain her consent, however, this was not consistent either with the clinical records or a letter sent to Mrs Hill in December 2008.
Caroline Freedman, Chairman of the Disciplinary Committee said: "The Committee is satisfied that Dr Jolaosho did not seek to obtain consent from Mrs Hill before he decided to carry out exploratory surgery. It does not consider that there was any attempt to explore treatment options with Mrs Hill before the surgery other than draining the mass."
On 16 June 2009, Dr Jolaosho pleaded guilty at Market Harborough Magistrates Court to two offences of docking the tails of Rottweiler and Doberman puppies. He was fined £10,000 and ordered to pay court costs of over £3,000. During 2003 to 2008, he was also convicted of 15 driving and related offences and twice of obstructing a police officer.
At the outset of the hearing, Dr Jolaosho admitted his criminal convictions, telling the Committee of his difficulties following the death of his wife in October 2002 and subsequent sole responsibility for his three teenage children. He also said that the tail docking resulted as an oversight on his part and that as the puppies were docked within five days of birth, there were no welfare issues. He emphasised that he had not carried out tail docking since being visited by the RSPCA in July 2008. He also drew to the Committee's attention the fact that, until 2003, he had been of good character.
The Committee accepted that for at least part of the period in question he was suffering from emotional problems following his wife's death, and his continuing financial responsibility for two of his children.
It was however, concerned, that having received a custodial sentence for driving whilst disqualified, he committed further driving offences on release. Nor did they accept that the tail docking was an oversight: in 2006 the RCVS advised Dr Jolaosho to comply with the RCVS Guide to Professional Conduct and not dock dog's tails unless for "truly therapeutic or prophylactic reasons." In view of the seriousness of the charges admitted and proved, the Committee concluded that a period of nine months suspension from the Register would be a proportionate penalty.
Mrs Freedman said: "The primary purpose of the sanctions is not to punish but to protect the welfare of animals, maintain public confidence in the profession, and declare and uphold proper standards of conduct."
She added: "Bearing in mind the financial consequences of the suspension of Mr Jolaosho, the Committee does not consider that any useful purpose would be served by imposing a longer period of suspension. However, Mr Jolaosho should be aware that any further convictions or failure to observe the College's Guidelines are likely to lead to the removal of his name from the Register."
The Recruitment Investment Group (RIG) has established a new recruitment agency that specialises in the supply of skilled professionals to the veterinary animal health market.
The newly formed RIG Animal Health Recruit will be working in the "industry" side of the profession to provide a permanent and temporary recruitment service in areas such as sales, technical product, academia, and laboratory work. The company's activities will not be confined to the UK alone, but, due the nature of this work, it will also operate in Europe.
The new company is headed up by James Roadnight, who has over 14 years' experience in working in specialist recruitment within professional and high integrity industries.
James said: "There comes a time in some vets or vet nurses' careers when they can want a change from working in practice and would like to move their skills to industry or academia. And we can help with this transition. Similarly, companies and institutions have a need to recruit personnel and will benefit from working with an agency that specialises only in this sector and should therefore have the strongest candidates available."
For more information, see www.rigahr.co.uk
The RCVS is calling for its members to nominate veterinary surgeons and non-veterinary surgeons who merit the award of Honorary Associateship or Honorary Fellowship.
Honorary Associates are awarded annually to people, not necessarily vets, by reason of their special eminence in, or special service to, the veterinary profession. Council has agreed that these should only be people ineligible for election as Honorary Fellows.
Honorary Fellowships can be awarded to up to three veterinary surgeons in any year for their service to, or special eminence in, the cause of veterinary science. Nominees for Honorary Fellowships must be members of the RCVS and have been a member, or held a registrable qualification, for at least 20 years.
Nominations must be received by the President, Mr Peter Jinman, by Friday 3 September 2010. Members can obtain nomination forms from the RCVS Executive Office (0207 202 0761 or executiveoffice@rcvs.org.uk).
All nominations need to include the particular reasons why the honour/award should be conferred, along with supporting statements from two referees, at least one of whom must not be a working colleague of the person nominated.
Nominations will be considered at the meeting of the Nominations Committee on 14 October, and awards made at RCVS Day on 1 July 2011. Details of Honorary Fellowship and Honorary Associateship award holders can be found in the Register of Veterinary Surgeons, with the addition since 2 July 2010 of Dr Tony Lawrence and Professor Martin Shirley (Honorary Associates), and Professor Elizabeth Simpson and Professor Peter Roeder (Honorary Fellowships).
CEVA Animal Health has now introduced Colibird, the UK's first colistin-based soluble antimicrobial approved for poultry.
According to the company, colistin is an important active in the UK's antimicrobial armoury, with a potent bactericidal action against Gram-negative bacteria, including enterobacteria and more particularly E. coli. Colibird is only one of a handful of products approved for layers that has a zero egg withhold. It also has almost zero levels of resistance, even with bugs variously resistant to other antimicrobials and is easily and efficiently administered in drinking water via header tanks or dosing pumps.
For further information please contact the large animal sales team or CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG.
Genitrix has announced the reformulation of Cerusolve, which cleans and deodorises the external ear canal of cats and dogs.
According to the company, the reformulation has enhanced Cerusolve's exfoliant and keratolyic properties and has given it a new fresh fragrance. Cerusolve ingredients now include:
Cerusolve is presented in a 100 ml bottle with a soft canula for application. It is priced at £5.65.
Genitrix Marketing Director Rob Watkins said: "Cerusolve has proved itself in practice as a gentle but effective ear cleaner in dogs and cats. The reformulation has given us the opportunity to increase the acidity of the product following a recent study which suggested that topical acidifying products could be therapeutically beneficial for cutaneous yeast infections.
"We believe the new ingredients will enhance the product and, to celebrate its arrival, we're offering practices the opportunity to buy five bottles of Cerusolve and get one free."
Further details are available from Genitrix on 01403 786345.
Seventeen overseas-qualified veterinary surgeons who succeeded in passing the Royal College of Veterinary Surgeons Statutory Examination for Membership, have been admitted to the RCVS Register and may now practise in the UK.
Remarkably, nearly half of them (8) were graduates of St George's University School of Veterinary Medicine (SGUSVM) in the Caribbean island of Grenada. Austin Kirwan, St George's Associate Dean of UK and Ireland Clinical Affairs said: "This outstanding result confirms the school's status as a leading international teaching institution for prospective veterinarians. Our graduates now have a proven record of high standards which is encouraging to those who follow in their footsteps."
To mark the occasion, a ceremony was held at Belgravia House for the registrants, their friends and families. After the veterinary surgeons' names were entered into the Register, RCVS President, Mr Peter Jinman, made a short address to welcome those attending, and presented the new Members with their certificates.
"Today is a celebration not just for those registering but for all of you," he said, acknowledging the importance of the support provided to vets by their friends and family. He also encouraged those who were newly graduated to sign up for the Professional Development Phase as the route to postgraduate education, saying that "Education does not stop today; indeed it is just a closing of one chapter and tomorrow is the opening of another, for learning is a lifelong experience."
Medichem International has produced an A4 sized laminated poster which illustrates the correct way to wash and disinfect hands thoroughly.
The poster has a sticky back enabling it to be placed near to hand washing facilities in the practice.
If you would like copies of the poster, they are available free of charge by emailing info@medichem.co.uk and stating your name, practice, address and postcode.
CEVA Animal Health has launched a double-sized version of Cyclo Spray, the company's chlorotetracycline-based treatment for the clinical symptoms of foot rot in sheep and digital dermatitis in cattle.
CEVA says that Cyclo Spray's superior spray performance makes it very cost-effective: the aerosol generates a narrow, condensed spray with limited dispersion for accurate application and minimal drip. The spray adheres cleanly and dries fast on the treatment area, to ensure that the antimicrobial has maximum efficacy within the shortest possible spray time.
CEVA adds that each spray of Cyclo Spray covers the skin with a concentration of chlorotetracycline that is thousands of times greater than is actually required to kill the causative bacteria.
The original size can is also available if required.
For further information contact CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG.
Vetoquinol is introducing Equistro Kerabol Biotin, a complementary feeding stuff for horses which the company says can help maintain healthy hoof and hair growth when used daily.
Equistro Kerabol Biotin will replace Biometh Z and will be automatically supplied in its place when wholesaler stocks of Biometh Z are exhausted.
Equistro Kerabol Biotin is a complex of D-biotin, methionine and Ipaligo zinc in combination with organic selenium and Ipaligo manganese.
Available as a powder in a 3kg bucket which will last 200 days, Vetoquinol says Equistro Kerabol Biotin offers a cost-effective method of ensuring good quality hoof horn.
For more information about any Equistro product, please call 0800 169197 or speak to your local equine territory manager.
A study by Janssen Animal Health has, according to the company, demonstrated that a leading herbal wormer had no demonstrable efficacy against common poultry worms1.
The trial, done to Good Clinical Practice (GCP) Standards, involved 48 chickens that had become naturally infected with three different poultry worms - Capillaria (Hairworm) species, Heterakis gallinarum (Caecal worm) and Ascaridia galii (Large roundworm). The birds were randomly assigned to one of three groups:
A. Flubenvet treated groupB. Herbal wormer treated groupC. Control (untreated) group.
The herbal treatment was administered for 3 days in-feed, as required by the 'on-pack' instructions and Flubenvet was given for 7 days as required on the product data sheet. Droppings were collected from individual birds and group pens at intervals for 2 weeks and examined for the presence of worm eggs
Table 1: Worm Count Summaries
Group
Minimum
Maximum
Median
A (Flubenvet treatment)
0.00
19.00
B (Herbal treatment)
108.00
1327.00
425.00
C (no treatment)
74.00
958.00
302.00
The results showed that very few worm eggs were present after one 7-day treatment with Flubenvet. In contrast, those that had no treatment or the herbal treatment still had hundreds of worm eggs in their droppings, suggesting that there were still many adult egg-laying worms present inside the chickens.
Janssen says poultry keepers who rely on preparations like this particular natural wormer may well be building up problems, as the additional numbers of worm eggs in the environment add to the infection pressure and can result in greater worm burdens for their birds. Birds with high worm burdens are more likely to become ill.
According to the Veterinary Medicines Regulations 2009 any product making veterinary medicinal claims needs to be licensed by the Veterinary Medicines Directorate. A licensed product has to show proven efficacy and safety for the animal species involved. Licensed veterinary medicines can be identified by their Vm number, which is shown on-pack. Products termed 'nutritional supplements', that are not licensed do not require the manufacturer to produce any proof of efficacy or safety. It is often easy to buy such products 'off the shelf' because they are not subject to any controls. Any poultry keeper who cares about the health and welfare of the birds is advised to think carefully about their choice of wormer and to seek advice from a vet pharmacist or Suitably Qualified Person (SQP).
1 Evaluation of the efficacy of flubendazole in comparison with a herbal wormer in the treatment of naturally acquired infections of Ascaridia galli, Heterakis gallinarum, and intestinal Capillaria spp in Chickens, Janssen Animal Health